Human variability and noncancer risk assessment--an analysis of the default uncertainty factor.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Regulatory toxicology and pharmacology : RTP

• Publication date

  1998-02-01

• Fields of study

  Medicine, Computer Science, Environmental Science

• Identifiers
  DOI 10.1006/RTPH.1997.1195PMID 9629592
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys

  2005cited by this paper
• N-desmethyladinazolam pharmacokinetics and behavioral effects following administration of 10–50 mg oral doses in healthy volunteers

  2005cited by this paper
• Clinical pharmacodynamics of continuous-infusion etoposide

  2004cited by this paper
• Pharmacodynamic model of the haemodynamic effects of pinacidil in normotensive volunteers

  2004cited by this paper
• Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects

  2004cited by this paper
• Disposition kinetics of metronidazole in children

  2004cited by this paper
• Experimental and clinical studies on the intraperitoneal administration of cis-diamminedichloroplatinum (II) for peritoneal carcinomatosis caused by gastric cancers

  2004cited by this paper
• Toxicokinetics in infants and children in relation to the ADI and TDI.

  1998cited by this paper
• Grapefruit juice—terfenadine single‐dose interaction: Magnitude, mechanism, and relevance

  1997cited by this paper
• Metabolic disposition of lansoprazole in relation to the S‐mephenytoin 4′‐hydroxylation phenotype status

  1997cited by this paper
• Jejunal permeability and hepatic extraction of fluvastatin in humans

  1996cited by this paper
• Interpatient variability in bioavailability is related to the extent of absorption: Implications for bioavailability and bioequivalence studies

  1996cited by this paper
• Inter-ethnic differences in xenobiotic metabolism.

  1996cited by this paper
• Pharmacodynamics and Pharmacokinetics of Two Dose Regimens of Befloxatone, a New Reversible and Selective Monoamine Oxidase Inhibitor, at Steady State in Healthy Volunteers

  1996cited by this paper
• Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response

  1996cited by this paper
• Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity.

  1996cited by this paper
• Population approaches/sparse data analysis for human variability in kinetics and dynamics.

  1996cited by this paper
• The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin

  1996cited by this paper
• The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans

  1996cited by this paper
• Evolution of science-based uncertainty factors in noncancer risk assessment.

  1996cited by this paper
• Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study *

  1995cited by this paper
• The use of an additional safety or uncertainty factor for nature of toxicity in the estimation of acceptable daily intake and tolerable daily intake values.

  1995cited by this paper
• Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization

  1995cited by this paper
• Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians.

  1995cited by this paper
• Clinical Pharmacokinetics of Newer Cephalosporins

  1995cited by this paper
• Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin‐dependent diabetes

  1995cited by this paper
• Scientific basis for uncertainty factors used to establish occupational exposure limits for pharmaceutical active ingredients

  1995cited by this paper
• Ethnic differences in response to morphine.

  1995cited by this paper
• Integrated pharmacokinetics and pharmacodynamics of the novel catechol‐O‐methyltransferase inhibitor tolcapone during first administration to humans

  1995cited by this paper
• Pharmacokinetics and pharmacodynamics of rocuronium at the vocal cords and the adductor pollicis in humans

  1995cited by this paper
• Racial differences in sensitivity to the negative chronotropic effects of propranolol in healthy men *

  1995cited by this paper
• A population model for the leukopenic effect of etoposide

  1995cited by this paper
• Pharmacokinetic‐pharmacodynamic modeling in drug development: Application to the investigational opioid trefentanil

  1994cited by this paper
• Pharmacokinetics and pharmacodynamics of MK‐383, a selective non‐peptide platelet glycoprotein‐IIb/IIIa receptor antagonist, in healthy men

  1994cited by this paper
• Pharmacokinetics and bioavailability of oral ergometrine in male volunteers

  1994cited by this paper
• Clinical enflurane metabolism by cytochrome P450 2E1.

  1994cited by this paper
• Characterization of the pharmacokinetics and pharmacodynamics of a new oral thromboxane A2‐receptor antagonist AA‐2414 in normal subjects: Population analysis

  1994cited by this paper
• Single‐dose kinetics of clomipramine: Relationship to the sparteine and S‐mephenytoin oxidation polymorphisms

  1994cited by this paper
• The concentration‐effect relationship of quinine‐induced hearing impairment

  1994cited by this paper
• The Teratogenic Metabolites of Vitamin A in Women Following Supplements and Liver

  1994cited by this paper
• Clinical enflurane metabolism by cytochrome P450 2E1

  1994cited by this paper
• Pharmacokinetics of naproxen, its metabolite O‐desmethylnaproxen, and their acyl glucuronides in humans

  1993cited by this paper
• Workshop on the scientific evaluation of the safety factor for the acceptable daily intake (ADI): editorial summary.

  1993cited by this paper
• Pharmacokinetics and pharmacodynamics of idrapril in rats, dogs, and humans.

  1993cited by this paper
• Data-derived safety factors for the evaluation of food additives and environmental contaminants.

  1993cited by this paper
• Racial Differences in the Pharmacokinetics of Methylprednisolone in Black and White Renal Transplant Recipients

  1993cited by this paper
• Pharmacokinetics of bromfenac in healthy subjects after single oral administration of three different doses.

  1993cited by this paper
• High-performance liquid chromatographic determination of total thiamine in human plasma for oral bioavailability studies.

  1993cited by this paper
• Influence of aging on the pharmacokinetics and pharmacodynamics of doxacurium

  1993cited by this paper
• Pharmacodynamic modeling of the antihypertensive response to amlodipine

  1993cited by this paper
• Pharmacokinetics of the gastrokinetic agent mosapride citrate after single and multiple oral administrations in healthy subjects.

  1993cited by this paper
• The influences of dose and ethnic origins on the pharmacokinetics of nifedipine

  1993cited by this paper
• Labetalol in Hypertension During the Third Trimester of Pregnancy: Its Antihypertensive Effect and Pharmacokinetic‐Dynamic Analysis

  1993cited by this paper
• Ethnic differences in response to morphine

  1993cited by this paper
• The pharmacokinetics of droperidol in anesthetized children.

  1993cited by this paper
• Interindividual variation in the capacity-limited renal glucuronidation of probenecid by humans

  1993cited by this paper
• Importance of Early Blood Sampling on Vecuronium Pharmacokinetic and Pharmacodynamic Parameters

  1993cited by this paper
• The metabolism of cyclamate to cyclohexylamine and its cardiovascular consequences in human volunteers.

  1992cited by this paper
• Pharmacodynamics of alfentanil. The role of plasma protein binding.

  1992cited by this paper
• Does the animal-to-human uncertainty factor incorporate interspecies differences in surface area?

  1992cited by this paper
• Plasma concentration — effect relationships for felodipine: A meta analysis

  1992cited by this paper
• Pharmacokinetic‐pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α‐hydroxymidazolam in healthy volunteers

  1992cited by this paper
• Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.

  1992cited by this paper
• Effect of age on ibuprofen pharmacokinetics and antipyretic response.

  1992cited by this paper
• Quantification of Theophylline-Induced Eosinopenia and Hypokalaemia in Healthy Volunteers

  1992cited by this paper
• Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability

  1992cited by this paper
• Pharmacodynamics of propofol in female patients.

  1992cited by this paper
• Quantification of metoprolol beta 2-adrenoceptor antagonism in asthmatic patients by pharmacokinetic-pharmacodynamic modelling.

  1992cited by this paper
• Racial differences in propranolol pharmacokinetics

  1992cited by this paper
• Evaluation of dose-related pharmacokinetics and pharmacodynamics of prednisolone in man

  1992cited by this paper
• Pharmacokinetics and Pharmacodynamics of Intravenous Diltiazem in Patients With Atrial Fibrillation or Atrial Flutter

  1992cited by this paper
• Clarithromycin Pharmacokinetics in Healthy Young and Elderly Volunteers

  1992cited by this paper
• The effects of age on the pharmacokinetics, antihypertensive efficacy and general tolerability of dilevalol.

  1991cited by this paper
• Pharmacokinetics of temafloxacin in humans after single oral doses

  1991cited by this paper
• Extent and Variability of the First-Pass Elimination of Adinazolam Mesylate in Healthy Male Volunteers

  1991cited by this paper
• Single-dose pharmacokinetics of ceftibuten (SCH 39720) in infants and children

  1991cited by this paper
• Pharmacokinetics of encainide in patients with cirrhosis

  1991cited by this paper
• Pharmacokinetics of temafloxacin in humans after single oral doses.

  1991cited by this paper
• A pharmacokinetic–pharmacodynamic model of heart rate during cocaine administration in humans

  1991cited by this paper
• Inter- and intraindividual variability in the concentration-effect (sedation) relationship of flunitrazepam.

  1991cited by this paper
• The concept of the acceptable daily intake: an historical review.

  1991cited by this paper
• Safety and pharmacokinetics of single dose intravenous ofloxacin in healthy volunteers.

  1991cited by this paper
• Safety factors and establishment of acceptable daily intakes.

  1991cited by this paper
• A population study of the pharmacokinetics of felodipine.

  1991cited by this paper
• Pharmacokinetic and Pharmacodynamic Profiles of Vapiprost, a Selective, Long‐Lasting Thromboxane Receptor Antagonist, After Single and Multiple Oral Administration to Healthy Volunteers

  1991cited by this paper
• Pharmacokinetics of cefroxadine after infusion to healthy volunteers.

  1990cited by this paper
• Disposition of pethidine in man under acidic urinary pH. 4. Kinetics after oral dose in caucasian, Chinese and Indian subjects.

  1990cited by this paper
• Safety and pharmacokinetics of intravenously administered trospectomycin sulfate.

  1990cited by this paper
• A new approach to deriving community exposure guidelines from "no-observed-adverse-effect levels".

  1990cited by this paper
• Steady-state infusions of opioids in human. II. Concentration-effect relationships and therapeutic margins.

  1990cited by this paper
• Simultaneous Modeling of the Pharmacokinetic and Pharmacodynamic Properties of Benzodiazepines. II. Triazolam

  1990cited by this paper
• Pharmacokinetic‐pharmacodynamic relationships of methadone infusions in patients with cancer pain

  1990cited by this paper
• Kinetic-dynamic relations and individual responses to enalapril.

  1990cited by this paper
• Uptake, distribution and elimination of alpha-pinene in man after exposure by inhalation.

  1990cited by this paper
• Pharmacokinetics of epanolol in elderly patients with stable angina pectoris.

  1990cited by this paper
• Pharmacodynamic Action and Pharmacokinetics of Moxonidine After Single Oral Administration in Hypertensive Patients

  1990cited by this paper
• Concentration-response relationships for salicylate-induced ototoxicity in normal volunteers.

  1989cited by this paper
• Verapamil disposition and cardiovascular effects in elderly patients after single intravenous and oral doses

  1989cited by this paper
• Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo

  1989cited by this paper
• Interindividual differences in beta-receptor density contribute to variability in response to beta-adrenoceptor antagonists.

  1989cited by this paper

• Theory and Model for Dynamics of Expected Potentially Affected Fraction as a Measure of Environmental Risk Due to Toxic Substance Accumulation

  2025cites this paper
• Incorporating new approach methods (NAMs) data in dose–response assessments: The future is now!

  2024cites this paper
• Data derived extrapolation factors (DDEFs) for rat to human interspecies extrapolation for the HPPD inhibitor mesotrione

  2024cites this paper
• Quantifying EDC Emissions from Consumer Products: A Novel Rapid Method and Its Application for Systematic Evaluation of Health Impacts.

  2024cites this paper
• Advancing understanding of human variability through toxicokinetic modeling, in vitro-in vivo extrapolation, and new approach methodologies

  2024cites this paper
• Current practice and recommendations for advancing how human variability and susceptibility are considered in chemical risk assessment

  2023cites this paper
• Modelling human variability in toxicokinetic and toxicodynamic processes using Bayesian meta‐analysis, physiologically‐based modelling and in vitro systems

  2021cites this paper
• Refining in vitro and in silico neurotoxicity approaches by accounting for interspecies and interindividual differences in toxicodynamics

  2021cites this paper
• An overview of current practices for regulatory risk assessment with lessons learnt from cosmetics in the European Union

  2021influential citation
• A pilot study: Relationship between Bisphenol A, Bisphenol A glucuronide and sex steroid hormone levels in cord blood in a South African population.

  2021cites this paper
• A broader view on deriving a reference dose for THC traces in foods

  2021influential citation
• Methods for evaluating variability in human health dose–response characterization

  2020cites this paper
• Tolerable intake values for leachables: Practical use of ISO 10993-17 standard

  2020cites this paper
• Application of a unified probabilistic framework to the dose-response assessment of acrolein

  2020cites this paper
• Acetylcholinesterase inhibition in electric eel and human donor blood: an in vitro approach to investigate interspecies differences and human variability in toxicodynamics

  2020cites this paper
• Thresholds and Endocrine Disruptors: An Endocrine Society Policy Perspective

  2020cites this paper
• Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors

  2020influential citation
• Preexisting diabetes mellitus had no effect on the no-observed-adverse-effect-level of acetaminophen in rats.

  2020cites this paper
• Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: Bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment.

  2020cites this paper
• Inter-ethnic differences in CYP3A4 metabolism: A Bayesian meta-analysis for the refinement of uncertainty factors in chemical risk assessment

  2019cites this paper
• A generic Bayesian hierarchical model for the meta-analysis of human population variability in kinetics and its applications in chemical risk assessment

  2019cites this paper
• Pediatric Safety of Polysorbates in Drug Formulations

  2019cites this paper
• Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds

  2019cites this paper
• Derivation of occupational exposure limits for airborne chemicals – Comparison of methods and protection levels prepared on behalf of :

  2019influential citation
• Major Principles and Concepts of Risk Assessment

  2019cites this paper
• Distribution of residual agricultural pesticides and their impact assessment on the survival of an endangered species.

  2019cites this paper
• Unraveling the Exposome: A Practical View

  2019cites this paper
• The Yin–Yang of CYP3A4: a Bayesian meta-analysis to quantify inhibition and induction of CYP3A4 metabolism in humans and refine uncertainty factors for mixture risk assessment

  2018cites this paper
• Finding synergies for 3Rs – Toxicokinetics and read‐across: Report from an EPAA partners' Forum

  2018cites this paper
• Principles underpinning the use of new methodologies in the risk assessment of cosmetic ingredients

  2018cites this paper
• Determination of Human Safe Metal Cation Concentrations in Surface Water Used to Prepare Drinking Water

  2018cites this paper
• A 13-week subchronic toxicity study of acetaminophen using an obese rat model.

  2018cites this paper
• Identification of novel uncertainty factors and thresholds of toxicological concern for health hazard and risk assessment: Application to cleaning product ingredients.

  2018cites this paper
• Characterization of Daily Dietary Intake and the Health Risk of Neonicotinoid Insecticides for the U.S. Population.

  2018cites this paper
• Assessing health risks from multiple environmental stressors: Moving from G×E to I×E.

  2018cites this paper
• Determination of Human Safe Metal Cation Concentrations in Surface Water Used to Prepare Drinking Water

  2018cites this paper
• Using Exposomics to Assess Cumulative Risks from Multiple Environmental Stressors

  2018cites this paper
• Altered susceptibility of an obese rat model to 13-week subchronic toxicity induced by 3-monochloropropane-1,2-diol.

  2017cites this paper
• Pharmacokinetic data reduce uncertainty in the acceptable daily intake for benzoic acid and its salts.

  2017cites this paper
• Evolution of chemical-specific adjustment factors (CSAF) based on recent international experience; increasing utility and facilitating regulatory acceptance

  2017cites this paper
• Chemical-specific adjustment factors (inter-species toxicokinetics) to establish the ADI for steviol glycosides.

  2016cites this paper
• PBPK-Based Probabilistic Risk Assessment for Total Chlorotriazines in Drinking Water

  2016cites this paper
• Bayesian methods for uncertainty factor application for derivation of reference values.

  2016influential citation
• Developmental and reproductive toxicity risk assessment for environmental agents

  2016cites this paper
• Skin sensitization quantitative risk assessment: A review of underlying assumptions.

  2016cites this paper
• Uncertainties in age- and gender-based health risk assessment for recreational bathing: Arsenic in Del Azul stream, Argentina

  2016cites this paper
• Uncertainty and variability in human exposure limits – a chemical-specific approach for ciprofloxacin and methotrexate

  2016influential citation
• Low Calorie Intense Sweeteners Safety Aspects

  2016cites this paper
• Chapter 9 – Human and Environmental Risk Characterization of Nanoparticles

  2016cites this paper
• Data collection on Combined Toxicity of Multiple Chemicals for Animal Health and Ecological Risk Assessment

  2015cites this paper
• Data collection on toxicokinetic and toxicodynamic interactions of chemical mixtures for human risk assessment

  2015cites this paper
• Методические подходы для оценки вторичного загрязнения питьевых вод и ее адекватной доочистки

  2015cites this paper
• Regulatory risk assessment approaches for synthetic mineral fibres.

  2015cites this paper
• Assessing Human Variability in Kinetics for Exposures to Multiple Environmental Chemicals: A Physiologically Based Pharmacokinetic Modeling Case Study with Dichloromethane, Benzene, Toluene, Ethylbenzene, and m-Xylene

  2015influential citation
• Safety Evaluation in the Elderly via Dermatological Exposure

  2015cites this paper
• Assessment of health risks resulting from early-life exposures: Are current chemical toxicity testing protocols and risk assessment methods adequate?

  2015cites this paper
• Assessment of human exposure to environmental sources of nickel in Europe: Inhalation exposure.

  2015cites this paper
• Towards a non-animal risk assessment for anti-androgenic effects in humans.

  2015cites this paper
• Uncertainties in human health risk assessment of environmental contaminants: A review and perspective.

  2015cites this paper
• Systems Biology and Biomarkers of Early Effects for Occupational Exposure Limit Setting

  2015cites this paper
• The Scientific Basis of Uncertainty Factors Used in Setting Occupational Exposure Limits

  2015cites this paper
• Risk Assessment of residual monomer migrating from acrylic polymers and causing Allergic Contact Dermatitis during normal handling and use.

  2014cites this paper
• Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing.

  2014cites this paper
• European Centre for Ecotoxicology and Toxicology of Chemicals

  2014cites this paper
• The role of in vitro methods as alternatives to animals in toxicity testing

  2014cites this paper
• Scientific Committee on Consumer Safety SCCS

  2014cites this paper
• Characterization of the human kinetic adjustment factor for the health risk assessment of environmental contaminants

  2014cites this paper
• A Comparative Pharmacokinetic Estimate of Mercury in U.S. Infants Following Yearly Exposures to Inactivated Influenza Vaccines Containing Thimerosal

  2014cites this paper
• Guidance for Applying Quantitative Data to Develop Data-Derived Extrapolation Factors for Interspecies and Intraspecies Extrapolation

  2014cites this paper
• The Past, Present, and Future of Chemical Risk Assessment

  2014cites this paper
• Philosophy and the Precautionary Principle: Science, Evidence, and Environmental Policy

  2014cites this paper
• Chemical-Specific Adjustment Factor (CSAF)

  2014cites this paper
• The sub-chronic oral toxicity of 1,3,5-trimethylbenzene in Sprague-Dawley rats.

  2014cites this paper
• Ecogenetics of mercury: From genetic polymorphisms and epigenetics to risk assessment and decision‐making

  2014cites this paper
• Adjustment factors for toluene, styrene and methyl chloride by population modeling of toxicokinetic variability.

  2014cites this paper
• The Journal of Toxicological Sciences

  2014cites this paper
• Advancing human health risk assessment: Integrating recent advisory committee recommendations

  2013cites this paper
• Development Of Worker Inhalation Derived No Effect Levels For Tungsten Compounds

  2013cites this paper
• Uncertainty of testing methods--what do we (want to) know?

  2013cites this paper
• Novel statistical modelling approaches for pesticide residues

  2013cites this paper
• Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the renal sodium glucose co-transporter 2.

  2013cites this paper
• Assessing the impact of child/adult differences in hepatic first-pass effect on the human kinetic adjustment factor for ingested toxicants.

  2013cites this paper
• From in vitro hepatic metabolic studies towards human health risk assessment: Two case studies of diuron and carbosulfan

  2013cites this paper
• Toxicological risk assessment of chemicals

  2013cites this paper
• Extreme Sensitivity and the Practical Implications of Risk Assessment Thresholds

  2013cites this paper
• Dispelling urban myths about default uncertainty factors in chemical risk assessment – sufficient protection against mixture effects?

  2013influential citation
• A Review of the Reference Dose and Reference Concentration Processes

  2013cites this paper
• Développement de modèles prédictifs de la toxicocinétique de substances organiques

  2013cites this paper
• Population effects and variability.

  2012cites this paper
• The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans.

  2012cites this paper
• A consistent and transparent approach for calculation of Derived No-Effect Levels (DNELs) for petroleum substances.

  2012cites this paper
• - Application of Sweeteners in Food and Drinks (Bakery, Confectionery, Dairy Products, Puddings, Fruit Products, Vegetables, Beverages, Sports Drinks, Hard Candies, Loukoumia, Marmalades, Jams, Jellies, Baked Goods, Sorbet)

  2012cites this paper
• Noncancer Risk Assessment: Principles and Practice in Environmental and Occupational Settings

  2012cites this paper
• Modeling the Human Kinetic Adjustment Factor for Inhaled Volatile Organic Chemicals: Whole Population Approach versus Distinct Subpopulation Approach

  2012cites this paper
• State of the Science: Biologically Based Modeling in Risk Assessment

  2012cites this paper
• Allowable limits for toxic leachables: practical use of ISO 10993-17 standard

  2012cites this paper
• Extrapolation, uncertainty factors, and the precautionary principle.

  2011cites this paper
• Just who is at risk? The ethics of environmental regulation

  2011cites this paper
• Trends and challenges in risk assessment of environmental contaminants

  2011cites this paper
• Safety of resveratrol with examples for high purity, trans‐resveratrol, resVida≫

  2011cites this paper